Loading
A phase 2 trial of Camizestrant and Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer is a phase 2 interventional study registered as NCT04214288 by AstraZeneca, with 240 participants enrolled, started 2020-04-22 and due to reach its primary completion in 2022-08-30. Interventions recorded: AZD9833 and Fulvestrant. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
240 enrolled.
90% CI 3.7 to 10.9; Figures from the ClinicalTrials.gov results section (first posted 2023-12-12), not from a publication · 90% CI 5.5 to 12.9 · 90% CI 1.9 to NA · 90% CI 2.0 to 6.0
SourceFigures from the ClinicalTrials.gov results section (first posted 2023-12-12), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS)primary | AZD9833 75mg | 74 | 7.2 months | - | - | link |
| AZD9833 150mg | 73 | 7.7 months | ||||
| AZD9833 300mg | 20 | 6.3 months | ||||
| Fulvestrant 500 mg | 73 | 3.7 months | ||||
| Objective Response Rate (ORR) | AZD9833 75mg | 70 | 15.7% | - | - | link |
| AZD9833 150mg | 65 | 17.1% | ||||
| AZD9833 300mg | 19 | 25.2% | ||||
| Fulvestrant 500 mg | 68 | 11.6% |
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Camizestrant, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.